🚀 VC round data is live in beta, check it out!
Lucid Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for Lucid Diagnostics and similar public comparables like InfuSystem, Carvolix, Bioneer, Anika Therapeutics and more.
Lucid Diagnostics Overview
About Lucid Diagnostics
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
Founded
2018
HQ
Employees
72
Website
Financials (LTM)
EV
$257M
Lucid Diagnostics Financials
Lucid Diagnostics reported last 12-month revenue of $6M and negative EBITDA of ($53M).
In the same LTM period, Lucid Diagnostics generated ($747K) in gross profit, ($53M) in EBITDA losses, and had net loss of ($55M).
Revenue (LTM)
Lucid Diagnostics P&L
In the most recent fiscal year, Lucid Diagnostics reported revenue of $5M and EBITDA of ($57M).
Lucid Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $6M | XXX | $5M | XXX | XXX | XXX |
| Gross Profit | ($747K) | XXX | ($2M) | XXX | XXX | XXX |
| Gross Margin | (12%) | XXX | (42%) | XXX | XXX | XXX |
| EBITDA | ($53M) | XXX | ($57M) | XXX | XXX | XXX |
| EBITDA Margin | (845%) | XXX | (1203%) | XXX | XXX | XXX |
| EBIT Margin | (767%) | XXX | (1030%) | XXX | XXX | XXX |
| Net Profit | ($55M) | XXX | ($58M) | XXX | XXX | XXX |
| Net Margin | (879%) | XXX | (1233%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Lucid Diagnostics Stock Performance
Lucid Diagnostics has current market cap of $212M, and enterprise value of $257M.
Market Cap Evolution
Lucid Diagnostics' stock price is $1.24.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $257M | $212M | 0.0% | XXX | XXX | XXX | $-0.34 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialLucid Diagnostics Valuation Multiples
Lucid Diagnostics trades at 41.1x EV/Revenue multiple, and (4.9x) EV/EBITDA.
EV / Revenue (LTM)
Lucid Diagnostics Financial Valuation Multiples
As of April 20, 2026, Lucid Diagnostics has market cap of $212M and EV of $257M.
Equity research analysts estimate Lucid Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lucid Diagnostics has a P/E ratio of (3.8x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $212M | XXX | $212M | XXX | XXX | XXX |
| EV (current) | $257M | XXX | $257M | XXX | XXX | XXX |
| EV/Revenue | 41.1x | XXX | 54.7x | XXX | XXX | XXX |
| EV/EBITDA | (4.9x) | XXX | (4.5x) | XXX | XXX | XXX |
| EV/EBIT | (5.4x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | (344.6x) | XXX | (131.1x) | XXX | XXX | XXX |
| P/E | (3.8x) | XXX | (3.7x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.5x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Lucid Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Lucid Diagnostics Margins & Growth Rates
Lucid Diagnostics' revenue in the last 12 month grew by 120%.
Lucid Diagnostics' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.7M for the same period.
Lucid Diagnostics' rule of 40 is (335%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lucid Diagnostics' rule of X is (169%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Lucid Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 120% | XXX | 111% | XXX | XXX | XXX |
| EBITDA Margin | (845%) | XXX | (1203%) | XXX | XXX | XXX |
| EBITDA Growth | (20%) | XXX | (22%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (335%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (169%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.7M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 291% | XXX | 376% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 386% | XXX | 511% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 91% | XXX | 121% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1013% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Lucid Diagnostics Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Lucid Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Carvolix | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioneer | XXX | XXX | XXX | XXX | XXX | XXX |
| Anika Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| EBR Systems | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lucid Diagnostics M&A Activity
Lucid Diagnostics acquired XXX companies to date.
Last acquisition by Lucid Diagnostics was on XXXXXXXX, XXXXX. Lucid Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Lucid Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialLucid Diagnostics Investment Activity
Lucid Diagnostics invested in XXX companies to date.
Lucid Diagnostics made its latest investment on XXXXXXXX, XXXXX. Lucid Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Lucid Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Lucid Diagnostics
| When was Lucid Diagnostics founded? | Lucid Diagnostics was founded in 2018. |
| Where is Lucid Diagnostics headquartered? | Lucid Diagnostics is headquartered in United States. |
| How many employees does Lucid Diagnostics have? | As of today, Lucid Diagnostics has over 72 employees. |
| Who is the CEO of Lucid Diagnostics? | Lucid Diagnostics' CEO is Lishan Aklog. |
| Is Lucid Diagnostics publicly listed? | Yes, Lucid Diagnostics is a public company listed on Nasdaq. |
| What is the stock symbol of Lucid Diagnostics? | Lucid Diagnostics trades under LUCD ticker. |
| When did Lucid Diagnostics go public? | Lucid Diagnostics went public in 2021. |
| Who are competitors of Lucid Diagnostics? | Lucid Diagnostics main competitors are InfuSystem, Carvolix, Bioneer, Anika Therapeutics. |
| What is the current market cap of Lucid Diagnostics? | Lucid Diagnostics' current market cap is $212M. |
| What is the current revenue of Lucid Diagnostics? | Lucid Diagnostics' last 12 months revenue is $6M. |
| What is the current revenue growth of Lucid Diagnostics? | Lucid Diagnostics revenue growth (NTM/LTM) is 120%. |
| What is the current EV/Revenue multiple of Lucid Diagnostics? | Current revenue multiple of Lucid Diagnostics is 41.1x. |
| Is Lucid Diagnostics profitable? | No, Lucid Diagnostics is not profitable. |
| What is the current EBITDA of Lucid Diagnostics? | Lucid Diagnostics has negative EBITDA and is not profitable. |
| What is Lucid Diagnostics' EBITDA margin? | Lucid Diagnostics' last 12 months EBITDA margin is (845%). |
| What is the current EV/EBITDA multiple of Lucid Diagnostics? | Current EBITDA multiple of Lucid Diagnostics is (4.9x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.